US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bicara Therapeutics

11.01

+1.1111.21%

Volume:3.06M

Turnover:32.89M

Market Cap:600.44M

PE:-3.61

High:11.21

Open:9.98

Low:9.71

Close:9.90

Loading ...

Overview Company News Filings

Wells Fargo Sticks to Its Hold Rating for Bicara Therapeutics Inc. (BCAX)

Bicara Therapeutics Inc. to Present at Goldman Sachs 46th Annual Global Healthcare Conference

Promising Efficacy of Bicara Therapeutics’ Ficera in Combination with Pembro for HPV-Negative HNSCC Justifies Buy Rating

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025

Sector Update: Health Care Stocks Decline Late Afternoon

MT Newswires Live

Wells Fargo Upgrades Bicara Therapeutics to Equal Weight From Underweight, $8 Price Target

MT Newswires Live

Bicara Therapeutics Shares Fall After Cancer Drug Trial Fails to Reach Survival Benchmark

MT Newswires Live

Bicara Therapeutics Raised to Equal-Weight From Underweight by Wells Fargo

Sector Update: Health Care Stocks Softer Friday Afternoon

MT Newswires Live

Top Midday Decliners

Wells upgrades Bicara to Equal Weight with thesis played out

Bicara Therapeutics upgraded to Equal Weight from Underweight at Wells Fargo

Nasdaq Down Over 1%; Workday Shares Tumble After Q1 Results

Why Is Bicara Therapeutics Stock (BCAX) Down 30% Today?

Wedbush Sticks to Its Buy Rating for Bicara Therapeutics Inc. (BCAX)

TD Cowen Keeps Their Buy Rating on Bicara Therapeutics Inc. (BCAX)

Bicara Therapeutics publishes updated data from Phase 1/1b trial of Ficerafusp

Bicara Therapeutics Announces Publication of an Abstract With Updated Interim Data From Phase 1/1B Trial of Ficerafusp Alfa in 1L R/M Hnscc at the 2025 Asco Annual Meeting

THOMSON REUTERS

Stock Track | Bicara Therapeutics Soars 5.11% Following TD Cowen's Buy Rating Reiteration

TD Cowen Keeps Their Buy Rating on Bicara Therapeutics Inc. (BCAX)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BCAX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BCAX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","market":"US","secType":"STK","nameCN":"Bicara Therapeutics","latestPrice":11.01,"timestamp":1748980800000,"preClose":9.9,"halted":0,"volume":3058182,"delay":0,"floatShares":28482543,"shares":54536218,"eps":-3.051868,"marketStatus":"Pre-Mkt","change":1.11,"latestTime":"06-04 07:06:37 EDT","open":9.98,"high":11.21,"low":9.7053,"amount":32887820.729826,"amplitude":0.15199,"askPrice":11.3,"askSize":5,"bidPrice":9.86,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.051868,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1749043800000},"marketStatusCode":1,"adr":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":11.01,"postHourTrading":{"tag":"盘后","latestPrice":11.05,"preClose":11.01,"latestTime":"19:35 EDT","volume":2861,"amount":31405.435,"timestamp":1748993702022},"volumeRatio":2.326086896730742,"impliedVol":1.4523,"impliedVolPercentile":0.9797},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","floatShares":28482543,"roa":"-13.84%","roe":"-27.26%","lyrEps":-4.045991,"volumeRatio":2.326086896730742,"shares":54536218,"dividePrice":0,"high":11.21,"amplitude":0.15199,"preClose":9.9,"low":9.7053,"week52Low":7.8,"pbRate":"1.31","week52High":28.09,"institutionHeld":0,"latestPrice":11.01,"committee":0.904762,"eps":-3.051868,"divideRate":0,"volume":3058182,"delay":0,"ttmEps":-3.051868,"open":9.98,"prevYearClose":17.42,"prevWeekClose":9.25,"prevMonthClose":9.25,"prevQuarterClose":13.03,"fiveDayClose":9.98,"twentyDayClose":14,"sixtyDayClose":16.55},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BCAX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540597130","title":"Wells Fargo Sticks to Its Hold Rating for Bicara Therapeutics Inc. (BCAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2540597130","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540597130?lang=en_us&edition=fundamental","pubTime":"2025-06-04 17:36","pubTimestamp":1749029799,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Eva Fortea Verdejo from Wells Fargo maintained a Hold rating on Bicara Therapeutics Inc. (BCAX – Research Report), ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wells-fargo-sticks-to-its-hold-rating-for-bicara-therapeutics-inc-bcax-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wells-fargo-sticks-to-its-hold-rating-for-bicara-therapeutics-inc-bcax-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX"],"gpt_icon":0},{"id":"2540704507","title":"Bicara Therapeutics Inc. to Present at Goldman Sachs 46th Annual Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2540704507","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540704507?lang=en_us&edition=fundamental","pubTime":"2025-06-04 04:01","pubTimestamp":1748980909,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, is set to participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025, at 3:20 p.m. ET. The company is committed to developing transformative bifunctional therapies for patients with solid tumors. A live webcast of the presentation will be available on Bicara's Investor Relations website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on June 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL3YfGX8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","IE00B64PRP62.GBP","LU2210149790.SGD","LU2471134523.USD","LU2237443549.SGD","IE00B3QW5Z07.USD","LU2237443895.HKD","LU1868837300.USD","LU1894683348.USD","LU2210150020.SGD","LU2095319765.USD","IE0004086264.USD","LU1868836591.USD","IE0004091025.USD","LU1868837136.USD","BK4588","LU0096364046.USD","LU1791807156.HKD","LU1894683264.USD","LU2237443382.USD","LU2750360641.GBP","BK4139","IE0002270589.USD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","IE0034235188.USD","IE00BKPKM429.USD","LU2471134952.CNY","LU1868836757.USD","LU0106831901.USD","BK4127","LU2237443978.SGD","IE00BSNM7G36.USD","LU2237438978.USD","NDAQ","LU0251142724.SGD","LU0742534661.SGD","BK4552","BK4516","BK4585","BK4550","LU0251131958.USD","LU2471134796.USD","LU0048573561.USD","IE00BGHQF748.EUR","BK4112","LU2750360997.AUD","BK4533","BK4504","LU1868836914.USD"],"gpt_icon":0},{"id":"2540648447","title":"Promising Efficacy of Bicara Therapeutics’ Ficera in Combination with Pembro for HPV-Negative HNSCC Justifies Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2540648447","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540648447?lang=en_us&edition=fundamental","pubTime":"2025-06-02 17:56","pubTimestamp":1748858162,"startTime":"0","endTime":"0","summary":"Analyst Judah Frommer from Morgan Stanley maintained a Buy rating on Bicara Therapeutics Inc. (BCAX – Research Report) and keeping the price target...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-efficacy-of-bicara-therapeutics-ficera-in-combination-with-pembro-for-hpv-negative-hnscc-justifies-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-efficacy-of-bicara-therapeutics-ficera-in-combination-with-pembro-for-hpv-negative-hnscc-justifies-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX"],"gpt_icon":0},{"id":"2540737112","title":"Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2540737112","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540737112?lang=en_us&edition=fundamental","pubTime":"2025-06-02 01:12","pubTimestamp":1748797920,"startTime":"0","endTime":"0","summary":"Median DOR of 21.7 months with 80% of responders achieving a deep response . Depth and durability translating to prolonged OS with median OS of 21.3 months and 2-year OS of 46% in HPV-negative HNSCC. Conference call and webcast today at 3:00 p.m. CT / 4:00 p.m. ET. In the Phase 1/1b trial, ficerafusp alfa in combination with pembrolizumab resulted in deep and durable anti-tumor activity with improved overall survival  compared to historical benchmarks in patients with 1L R/M human papillomavirus-negative HNSCC with a PD-L1 combined positive score  of ≥1 and with at least 24 months of follow-up.In the efficacy evaluable human papillomavirus-negative population :. Median OS of 21.3 months; 2-year OS rate of 46%.54%  confirmed objective response rate ; 64%  ORR, including an additional three unconfirmed responses.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bicara-therapeutics-demonstrates-deep-durable-171200341.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4124","OS","CPS","BK4139","BK4097","BCAX","ORR"],"gpt_icon":0},{"id":"2537715467","title":"Sector Update: Health Care Stocks Decline Late Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2537715467","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537715467?lang=en_us&edition=fundamental","pubTime":"2025-05-24 03:56","pubTimestamp":1748030179,"startTime":"0","endTime":"0","summary":"Health care stocks retreated late Friday afternoon, with the NYSE Health Care Index down 0.2% and the Health Care Select Sector SPDR Fund  shedding 0.3%.The iShares Biotechnology ETF  was down 0.1%.In corporate news, Vivos Therapeutics  shares jumped 9% after the company said it issued a $1.1 million convertible promissory note to V-Co Investors 2, with proceeds to be used for the acquisition of The Sleep Center of Nevada.Bicara Therapeutics  shares fell 43% after the company said late Thursday that its latest trial for a potential head and neck cancer treatment has yet to reach median overall survival.Merus  shares surged 32% after the company reported favorable interim cancer trial results in the previous day.Imunon  shares rallied 175%. It reported positive data showing an improvement in overall and progression-free survival from a phase 2 trial of IMNN-001 in ovarian cancer.Fulcrum Therapeutics  shares gained 5% after Leerink upgraded the stock to outperform from market perform and","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IBB","BCAX","BK4139","LU0109394709.USD","FULC","BK4007","MRUS","VVOS","BK4196","BK4585","IMNN","XLV","BK4581","BK4588","LU0320765992.SGD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2537159087","title":"Wells Fargo Upgrades Bicara Therapeutics to Equal Weight From Underweight, $8 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2537159087","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537159087?lang=en_us&edition=fundamental","pubTime":"2025-05-24 02:44","pubTimestamp":1748025849,"startTime":"0","endTime":"0","summary":"Price: 8.73, Change: -6.93, Percent Change: -44.25","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BCAX"],"gpt_icon":0},{"id":"2537159995","title":"Bicara Therapeutics Shares Fall After Cancer Drug Trial Fails to Reach Survival Benchmark","url":"https://stock-news.laohu8.com/highlight/detail?id=2537159995","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537159995?lang=en_us&edition=fundamental","pubTime":"2025-05-24 02:20","pubTimestamp":1748024407,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics (BCAX) shares fell 44% in recent trading Friday, a day after the company said that its latest clinical trial for a potential head and neck cancer treatment has yet to reach median ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2537977159","title":"Bicara Therapeutics Raised to Equal-Weight From Underweight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2537977159","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537977159?lang=en_us&edition=fundamental","pubTime":"2025-05-24 02:20","pubTimestamp":1748024400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BCAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 23, 2025 14:20 ET (18:20 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX"],"gpt_icon":0},{"id":"2537159580","title":"Sector Update: Health Care Stocks Softer Friday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2537159580","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537159580?lang=en_us&edition=fundamental","pubTime":"2025-05-24 02:04","pubTimestamp":1748023448,"startTime":"0","endTime":"0","summary":"Health care stocks declined Friday afternoon with the NYSE Health Care Index down 0.4% and the Health Care Select Sector SPDR Fund  falling 0.2%.The iShares Biotechnology ETF  decreased 0.3%.In corporate news, Medtronic  shares fell 0.7%. JPMorgan cut its price target on the stock to $87 from $95.Bicara Therapeutics  shares tumbled 45%, a day after the company said its phase 1/1b trial of ficerafusp alfa with pembrolizumab in people with head and neck squamous cell carcinoma hasn't yet reached median overall survival and median duration of response based on interim results.Imunon  shares more than doubled. The company received positive data showing an improvement in overall and progression-free survival from a phase 2 trial of IMNN-001, an investigational therapy to treat ovarian cancer.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0265550946.USD","BK4139","IE00BQXX3F31.USD","IE00BFXG1179.USD","IE00BQXX3C00.GBP","LU1571399168.USD","LU2089984988.USD","IE000M9KFDE8.USD","LU1983299246.USD","LU0162691827.USD","BK4533","LU0208291251.USD","LU0211331839.USD","LU0320765489.SGD","LU0976567544.SGD","LU2271345857.HKD","IE00B3T34201.USD","LU2468319806.SGD","LU0211326755.USD","IMNM","BK4566","LU0211326839.USD","LU1291159041.SGD","LU0265550359.USD","IBB","LU2028103732.USD","LU1116320901.HKD","LU2111349929.HKD","BK4563","LU2023251221.USD","XLV","LU0496365809.HKD","LU1989764664.SGD","LU0070302665.USD","BK4585","MDT","BCAX","IMNN","BK4581","LU0072461881.USD","LU1989764748.USD","LU2089284900.SGD","BK4082","LU1116320737.USD","LU2089283258.USD","LU0158827781.USD","LU0158827948.USD","BK4588","LU1989771016.USD","IE00BQXX3D17.EUR"],"gpt_icon":0},{"id":"2538115976","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2538115976","media":"MT Newswires","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538115976?lang=en_us&edition=fundamental","pubTime":"2025-05-24 01:49","pubTimestamp":1748022541,"startTime":"0","endTime":"0","summary":"More than 5.19 million shares traded intraday compared with a daily average of about 588,000.Deckers Outdoor's  strong fiscal Q4 results were overshadowed by sales growth deceleration at its Hoka sneaker brand and potential demand weakness from price increases, prompting KeyBanc Capital Markets to downgrade the footwear and apparel company's stock.Ross Stores  overnight warned that elevated tariffs could pressure profitability, noting that over half its merchandise originates from China despite limited direct imports. Citing ongoing macroeconomic uncertainty and shifting trade policies, the company withdrew its full-year sales and earnings guidance.Shares declined 10%, with intraday trading volume rising to over 13.1 million versus a daily average of about 3.2 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/top-midday-decliners-174901220.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DECK","ROST","LU0266013472.USD","BK4588","BK4146","BK4139","BK4585","BCAX","BK4567","BK4094","LU1718418525.SGD"],"gpt_icon":0},{"id":"2537156831","title":"Wells upgrades Bicara to Equal Weight with thesis played out","url":"https://stock-news.laohu8.com/highlight/detail?id=2537156831","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537156831?lang=en_us&edition=fundamental","pubTime":"2025-05-24 01:00","pubTimestamp":1748019621,"startTime":"0","endTime":"0","summary":"Wells Fargo upgraded Bicara Therapeutics (BCAX) to Equal Weight from Underweight with an unchanged price target of $8. The form says its Underweigh...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/wells-upgrades-bicara-to-equal-weight-with-thesis-played-out-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/wells-upgrades-bicara-to-equal-weight-with-thesis-played-out-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0070302665.USD","LU1267930573.SGD","LU1363072403.SGD","BCAX","IE00B19Z3581.USD","IE00B7SZLL34.SGD","LU0787776722.HKD","LU0106831901.USD","LU0640476718.USD","LU0211327993.USD","LU0310799852.SGD","LU1035773651.USD","LU2361044949.HKD","LU0980610538.SGD","LU0130517989.USD","LU0052756011.USD","LU1267930490.SGD","LU0310800379.SGD","LU0971096721.USD","LU0256863811.USD","LU1201861249.SGD","LU0175139822.USD","LU0251142724.SGD","LU2461242641.AUD","LU1814569148.SGD","LU0310800965.SGD","LU0208291251.USD","LU0417517546.SGD","BK4559","LU0477156953.USD","LU1791807156.HKD","LU0267386448.USD","LU2236285917.USD","LU0708994859.HKD","BK4501","LU0149725797.USD","LU0289960550.SGD","LU1668664300.SGD","LU0048573561.USD","LU0072461881.USD","BK4207","BK4139","LU1280957306.USD","LU0128525689.USD","LU0128525929.USD","LU2361044865.SGD","LU0251131958.USD","LU0130102774.USD","IE0002270589.USD","IE00B19Z3B42.SGD"],"gpt_icon":0},{"id":"2537115681","title":"Bicara Therapeutics upgraded to Equal Weight from Underweight at Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2537115681","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537115681?lang=en_us&edition=fundamental","pubTime":"2025-05-24 00:55","pubTimestamp":1748019327,"startTime":"0","endTime":"0","summary":"Wells Fargo analyst Eva Fortea Verdejo upgraded Bicara Therapeutics (BCAX) to Equal Weight from Underweight with an unchanged price target of $8. P...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-upgraded-to-equal-weight-from-underweight-at-wells-fargo-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-upgraded-to-equal-weight-from-underweight-at-wells-fargo-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX"],"gpt_icon":0},{"id":"2537137445","title":"Nasdaq Down Over 1%; Workday Shares Tumble After Q1 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2537137445","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537137445?lang=en_us&edition=fundamental","pubTime":"2025-05-23 22:22","pubTimestamp":1748010160,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"aba9b9dfbecc08c5ef60da8bb18e3893","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/05/45588721/nasdaq-down-over-1-workday-shares-tumble-after-q1-results","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QLD","LU0082616367.USD","LU2517655374.HKD","BK4112","BK4216","BK4548","NQmain","LU1935042991.SGD","LU2517655291.USD","LU2095319765.USD","IE00BKPKM429.USD","GDHG","IE00B64PRP62.GBP","IMNN","MNQmain","NTCL","PMAX","IE00B3QW5Z07.USD","BK4581","NVIW.SI","LU0314104364.USD","IE0004445239.USD","SQQQ","LU1935043536.SGD","TQQQ","LU2517655028.SGD","PSQ","BK4585","LU1235294995.USD","USJW.SI","LU1989773731.SGD","QQQ","LU2265009873.SGD","NDAQ","BCAX","LU1823568750.SGD","QID","BK4204","LU2210149790.SGD","LU1691799644.USD",".IXIC","BK4613","USAW.SI","BLMZ","LU0719512351.SGD","IE00BGHQF748.EUR","TSYW.SI","BK4528","BK4139","WDAY"],"gpt_icon":0},{"id":"2537305132","title":"Why Is Bicara Therapeutics Stock (BCAX) Down 30% Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2537305132","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537305132?lang=en_us&edition=fundamental","pubTime":"2025-05-23 21:35","pubTimestamp":1748007345,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics stock plummeted on Friday as BCAX investors reacted negatively to the company’s latest clinical trial data.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/why-is-bicara-therapeutics-stock-bcax-down-30-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/why-is-bicara-therapeutics-stock-bcax-down-30-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2537314661","title":"Wedbush Sticks to Its Buy Rating for Bicara Therapeutics Inc. (BCAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2537314661","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537314661?lang=en_us&edition=fundamental","pubTime":"2025-05-23 20:45","pubTimestamp":1748004344,"startTime":"0","endTime":"0","summary":"Wedbush analyst David Nierengarten maintained a Buy rating on Bicara Therapeutics Inc. (BCAX – Research Report) today and set a price target of $30...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-sticks-to-its-buy-rating-for-bicara-therapeutics-inc-bcax?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-sticks-to-its-buy-rating-for-bicara-therapeutics-inc-bcax?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX"],"gpt_icon":0},{"id":"2537135487","title":"TD Cowen Keeps Their Buy Rating on Bicara Therapeutics Inc. (BCAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2537135487","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537135487?lang=en_us&edition=fundamental","pubTime":"2025-05-23 19:36","pubTimestamp":1748000165,"startTime":"0","endTime":"0","summary":"In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Bicara Therapeutics Inc. (BCAX – Research Report). The company...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-keeps-their-buy-rating-on-bicara-therapeutics-inc-bcax-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-keeps-their-buy-rating-on-bicara-therapeutics-inc-bcax-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TD","COWN","BCAX"],"gpt_icon":0},{"id":"2537973347","title":"Bicara Therapeutics publishes updated data from Phase 1/1b trial of Ficerafusp","url":"https://stock-news.laohu8.com/highlight/detail?id=2537973347","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537973347?lang=en_us&edition=fundamental","pubTime":"2025-05-23 06:55","pubTimestamp":1747954515,"startTime":"0","endTime":"0","summary":"The company states: “Bicara Therapeutics (BCAX) announced the publication of an abstract with updated interim data from the company’s Phase 1/1b cl...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-publishes-updated-data-from-phase-1-1b-trial-of-ficerafusp-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-publishes-updated-data-from-phase-1-1b-trial-of-ficerafusp-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2537927480","title":"Bicara Therapeutics Announces Publication of an Abstract With Updated Interim Data From Phase 1/1B Trial of Ficerafusp Alfa in 1L R/M Hnscc at the 2025 Asco Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2537927480","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537927480?lang=en_us&edition=fundamental","pubTime":"2025-05-23 05:00","pubTimestamp":1747947600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nTUA8YXHG0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"1198858469","title":"Stock Track | Bicara Therapeutics Soars 5.11% Following TD Cowen's Buy Rating Reiteration","url":"https://stock-news.laohu8.com/highlight/detail?id=1198858469","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198858469?lang=en_us&edition=fundamental","pubTime":"2025-05-20 02:41","pubTimestamp":1747680067,"startTime":"0","endTime":"0","summary":"Shares of Bicara Therapeutics  experienced a significant surge during Monday's intraday trading, climbing 5.11% as investors responded positively to a reaffirmed analyst rating. The biotechnology company's stock movement caught the attention of market participants amid broader sector fluctuations.The catalyst for this upward momentum appears to be tied to TD Cowen's latest analysis. Analyst Tyler Van Buren maintained a Buy rating on Bicara Therapeutics, signaling continued confidence in the comp","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Bicara Therapeutics Soars 5.11% Following TD Cowen's Buy Rating Reiteration","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["BCAX"],"gpt_icon":0},{"id":"2536686709","title":"TD Cowen Keeps Their Buy Rating on Bicara Therapeutics Inc. (BCAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2536686709","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536686709?lang=en_us&edition=fundamental","pubTime":"2025-05-19 19:35","pubTimestamp":1747654520,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tyler Van Buren maintained a Buy rating on Bicara Therapeutics Inc. (BCAX – Research Report) today. The company’s shares closed la...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-keeps-their-buy-rating-on-bicara-therapeutics-inc-bcax?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-keeps-their-buy-rating-on-bicara-therapeutics-inc-bcax?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX","TD","COWN"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":65,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BCAX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-13","symbol":"BCAX","fiscalQuarterEnding":"2025/03","expectedEps":-0.4,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2025-03-27","symbol":"BCAX","fiscalQuarterEnding":"2024/12","expectedEps":-0.31,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"pre","actualEps":-0.39},{"market":"US","date":"2024-11-12","symbol":"BCAX","fiscalQuarterEnding":"2024/09","expectedEps":-0.46,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.6}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BCAX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BCAX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2857,"buy":0.5714,"hold":0.1429,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5714,"analysts":7,"updateTime":1748059200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BCAX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BCAX","date":"2025-06-03","current":-5.847406,"percent":0.977654,"low":-22.704836,"twenty":-18.85835,"median":-12.579351,"eighty":-10.745093,"high":-5.463486,"avg":-14.170055,"sd":4.31814,"marketCap":539908558},"quantilePoints":[{"date":"2024-09-13","current":-12.837909,"twenty":-12.837909,"median":-12.837909,"eighty":-12.837909,"marketCap":832435719},{"date":"2024-09-20","current":-20.633135,"twenty":-21.391361,"median":-20.283845,"eighty":-14.007791,"marketCap":1337893755},{"date":"2024-09-27","current":-21.555755,"twenty":-21.594337,"median":-21.446718,"eighty":-19.006626,"marketCap":1397718272},{"date":"2024-10-04","current":-19.962139,"twenty":-21.575885,"median":-21.337681,"eighty":-19.559541,"marketCap":1294385015},{"date":"2024-10-11","current":-15.936161,"twenty":-21.540658,"median":-20.570229,"eighty":-18.732598,"marketCap":1033332575},{"date":"2024-10-18","current":-17.143955,"twenty":-21.466848,"median":-20.283845,"eighty":-16.808457,"marketCap":1111648307},{"date":"2024-10-25","current":-18.964032,"twenty":-21.403103,"median":-19.23243,"eighty":-16.959431,"marketCap":1229665764},{"date":"2024-10-31","current":-19.878264,"twenty":-21.362844,"median":-19.23243,"eighty":-17.02653,"marketCap":1288946422},{"date":"2024-11-08","current":-19.79439,"twenty":-21.337681,"median":-19.82794,"eighty":-17.143955,"marketCap":1283507830},{"date":"2024-11-15","current":-20.345116,"twenty":-21.127995,"median":-19.949558,"eighty":-18.418848,"marketCap":1210086831},{"date":"2024-11-22","current":-16.257533,"twenty":-21.102833,"median":-19.82794,"eighty":-17.143955,"marketCap":966965549},{"date":"2024-11-29","current":-19.02049,"twenty":-20.975343,"median":-19.458892,"eighty":-17.009755,"marketCap":1131300719},{"date":"2024-12-06","current":-17.876882,"twenty":-20.695202,"median":-19.01323,"eighty":-17.12047,"marketCap":1063281195},{"date":"2024-12-13","current":-16.509127,"twenty":-20.532485,"median":-19.005969,"eighty":-17.12047,"marketCap":981929844},{"date":"2024-12-20","current":-15.187116,"twenty":-20.493904,"median":-18.892739,"eighty":-16.769874,"marketCap":903299275},{"date":"2024-12-27","current":-17.49263,"twenty":-20.458153,"median":-18.854995,"eighty":-16.764842,"marketCap":1040426635},{"date":"2025-01-03","current":-15.484454,"twenty":-20.399979,"median":-18.727694,"eighty":-16.641786,"marketCap":920984351},{"date":"2025-01-10","current":-13.952019,"twenty":-20.332862,"median":-18.565256,"eighty":-16.325863,"marketCap":829838189},{"date":"2025-01-17","current":-10.868852,"twenty":-20.271506,"median":-18.306879,"eighty":-15.951961,"marketCap":646457553},{"date":"2025-01-24","current":-10.951191,"twenty":-20.22215,"median":-18.224539,"eighty":-15.55307,"marketCap":651354959},{"date":"2025-01-31","current":-11.811185,"twenty":-20.138275,"median":-17.666458,"eighty":-14.949245,"marketCap":702505641},{"date":"2025-02-07","current":-11.52757,"twenty":-20.11652,"median":-17.561246,"eighty":-13.156068,"marketCap":685636799},{"date":"2025-02-14","current":-12.003311,"twenty":-19.978914,"median":-17.49263,"eighty":-12.003311,"marketCap":713932921},{"date":"2025-02-21","current":-12.643731,"twenty":-19.965494,"median":-17.085242,"eighty":-11.997822,"marketCap":752023854},{"date":"2025-02-28","current":-11.307997,"twenty":-19.942009,"median":-16.815614,"eighty":-11.891694,"marketCap":672577050},{"date":"2025-03-07","current":-14.409462,"twenty":-19.890007,"median":-16.73236,"eighty":-11.891694,"marketCap":857045999},{"date":"2025-03-14","current":-12.213735,"twenty":-19.838005,"median":-16.60519,"eighty":-11.893524,"marketCap":726448513},{"date":"2025-03-21","current":-11.975864,"twenty":-19.8011,"median":-16.394587,"eighty":-11.882546,"marketCap":712300452},{"date":"2025-03-28","current":-10.745093,"twenty":-19.525992,"median":-16.092853,"eighty":-11.882546,"marketCap":730612568},{"date":"2025-04-04","current":-9.486153,"twenty":-19.364339,"median":-15.936742,"eighty":-11.721526,"marketCap":645010946},{"date":"2025-04-11","current":-8.139007,"twenty":-19.311424,"median":-15.55307,"eighty":-11.500123,"marketCap":553411758},{"date":"2025-04-17","current":-9.430022,"twenty":-19.133936,"median":-15.269456,"eighty":-11.355571,"marketCap":641194313},{"date":"2025-04-25","current":-12.533268,"twenty":-19.02049,"median":-15.045308,"eighty":-11.297018,"marketCap":852199585},{"date":"2025-05-02","current":-11.795546,"twenty":-19.011777,"median":-14.409462,"eighty":-11.329955,"marketCap":802038125},{"date":"2025-05-09","current":-10.531076,"twenty":-18.980807,"median":-14.002338,"eighty":-11.242349,"marketCap":716060542},{"date":"2025-05-16","current":-8.546663,"twenty":-18.933837,"median":-13.265854,"eighty":-11.091295,"marketCap":789139074},{"date":"2025-05-23","current":-9.249533,"twenty":-18.888545,"median":-12.837909,"eighty":-10.95668,"marketCap":854037173},{"date":"2025-05-30","current":-5.575709,"twenty":-18.86506,"median":-12.634583,"eighty":-10.80298,"marketCap":514821897},{"date":"2025-06-03","current":-5.847406,"twenty":-18.85835,"median":-12.579351,"eighty":-10.745093,"marketCap":539908558}],"updateTime":1749034921826}}}